TABLE 4.
Past and present phase II/III clinical trials with oncolytic virotherapy in glioblastoma.
| Clinical trial | Duration | Phase | Virus type | Treatment | Control | Indication | Outcome | References |
|---|---|---|---|---|---|---|---|---|
| NCT04482933 | 2021- | II | Herpes simplex virus | HSV G207 | None | Recurrent high grade glioma | NR | (MD GKF, 2021) |
| NCT02798406 CAPTIVE/KEYNOTE 192 | 2016–2021 | II | Adenovirus | DNX 2401 + pembrolizumab (n = 49) | None | rGBM | Median OS: 12.5 months | BioSpace Press release |
| NCT02986178 | 2017- | II | Poliovirus | PVS-RIPO (n = 122) | None | rGBM | NR | (UHSCC, 2021) |
| NCT04479241 LUMINOS-101 | 2020- | II | Poliovirus | PVS-RIPO + pembrolizumab (n = 30) | None | rGBM | NR | (Sloan et al., 2021) |
| NCT01174537 | NA | I/II | Newcastle disease virus | NDV-HUJ (n = 14) | None | rGBM | PFS range: 2–37 weeks OS range: 3–66 weeks | (Freeman et al., 2006) |
| NA | Published 1998 | I/II | Replicating Retrovirus | HSV-tk (n = 12) | None | rGBM | OS-12: 25% | (Klatzmann et al., 1998) |
| NA | Published 1999 | I/II | Replicating Retrovirus | HSV-tk (n = 48) | None | rGBM | OS-12: 27% | (Shand et al., 1999) |
| NA | Published 2004 | III | Replicating Retrovirus | HSV-tk + SOC (n = 124) | SOC (n = 124) | ndGBM | OS-12: 50 vs 55% (treatment vs control) | (Rainov, 2000) |
| NCT02414165 | 2015–2019 | II | Replicating Retrovirus | Toca 511 (n = 201) | SOC (n = 202) | ndGBM & rGBM | Median OS: 11.1 vs 12.2 mth (treatment vs control) | (Cloughesy et al., 2020) |